Login to Your Account



Pharma: Clinic Roundup


Thursday, May 16, 2013
• Sanofi SA, of Paris, and Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., enrolled their first patients in Phase III COMPARE and ASCERTAIN trials of sarilumab, for patients with moderate to severe rheumatoid arthritis (RA) who have not responded to methotrexate or tumor necrosis factor alpha inhibitor therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription